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Objective: To investigate the pharmacokinetic properties of pitavastatin in healthy Chinese volunteers
after single-dose and multiple-dose administration.
Methods: An open-label, randomized, single-dose and multiple-dose study was conducted in healthy
Chinese volunteers. The study included 4 stages, each separated with a 5-day washout period. A
randomized, 3-way crossover design was carried out in Stages 1 to 3 for the single-dose study. Eligible
subjects were randomized to receive a single 1 mg, 2 mg, or 4 mg pitavastatin calcium tablet. Blood
samples were obtained predose and up to 36 hours following dosing. In Stage 4 the subjects received a
2-mg pitavastatin calcium tablet once daily for 6 days. At the last day of multiple dosing, blood samples
were collected predose and up to 48 hours following dosing. Plasma pitavastatin was quantiﬁed by a
validated liquid chromatography tandem mass spectrometry method. Tolerability was assessed by the
adverse events, physical examination, 12-lead ECG, and laboratory tests.
Results: Twelve volunteers (6 male and 6 female) were enrolled in the study and 11 of them completed all
4 study stages. Following a single dose of 1 mg, 2 mg, and 4 mg, the mean (SD) Tmax values were 0.63 (0.17)
hours, 0.65 (0.17) hours, and 0.79 (0.36) hours, respectively; the corresponding Cmax values were 66.80 (16.32)
ng/mL, 106.09 (31.59) ng/mL, and 232.91 (66.42) ng/mL, respectively. AUC036 values were 190.04 (38.97) ng/
mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h, respectively, whereas t1/2 values were 10.99 (2.70)
hours, 9.52 (2.58) hours, and 10.38 (4.28) hours, respectively. The AUC and Cmax showed dose proportionality
after single dosing according to linear-regression analysis. In the multiple-dose study, a rapid absorption (Tmax
of 0.68 [0.20] hours) and marked peak concentration of 90.99 (36.88) ng/mL were observed. AUC048 and
AUCss were 306.28 (130.02) ng/mL/h and 256.16 (116.34) ng/mL/h, respectively. The elimination half-life after
multiple dosing was signiﬁcantly prolonged, which amounted to 13.31 (2.58) hours. Comparison of the
pharmacokinetic parameters between the male and female groups revealed no signiﬁcant differences.
Conclusions: In healthy Chinese volunteers, single dosing of 1 mg, 2 mg, and 4 mg pitavastatin resulted in
linear plasma pharmacokinetic properties. Compared with single dosing, multiple dosing of pitavastatin
showed different distribution and elimination characteristics. Sex did not appear to affect the pharmacokinetic
properties of pitavastatin. Chictr.org identiﬁer: ChiCTR-OO-13004294.
& 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Among the numerous medications for the treatment of hyper-
lipidemia, no class of drugs is so widely prescribed as 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors,Inc. This is an open access article u
titute of Drug Clinical Trials,
oxuexiang Chengdu 610041which are also known as statins.1 Many previous studies have
demonstrated the favorable efﬁcacy and safety proﬁles of statins in
modifying lipid levels and also the effects of lowering the morbid-
ity and mortality of coronary heart disease.2–5 Pitavastatin is a
newly developed HMG-CoA reductase inhibitor approved for the
treatment of hyperlipidemia.6 Pitavastatin’s effects on lipid param-
eters have been reported to be signiﬁcant, and the safety proﬁle
comparable with those of other statins such as atorvastatin,
simvastatin, and pravastatin.7–9 Pitavastatin calcium has been
available for clinical use in Japan since 2003 and also has approvalnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the treatment of hypercholesterolemia and combined dyslipide-
mia by the US Food and Drug Administration.10
Pharmacokinetic (PK) properties and clinical pharmacology of
pitavastatin have been studied previously.11 Pitavastatin’s PK data
are also available for a Chinese population, including female
patients and those receiving multiple-dose administration.12 To
add more data to the already published literature, our study was
conducted to investigate the PK properties of pitavastatin in healthy
male and female Chinese volunteers receiving single- and multiple-
dose administration. This was a registered study approved by the
China Food and Drug Administration (approval No. 2005L04730).Subjects and Methods
Study design
This was an open-label, randomized, single- and multiple-dose
PK study that planned to enroll 12 (6 male and 6 female) healthy
Chinese volunteers. The study included 4 stages, each separated
with a 5-day washout period. Stages 1 to 3 are the single-dose study
stages in which a randomized, 3-way crossover design was carried
out. Based on a computer-generated table of random numbers,
12 subjects were allocated in a 1:1:1 ratio to receive a single 1 mg,
2 mg, or 4 mg pitavastatin calcium tablet in randomized sequence.
Stage 4 is the multiple-dose study stage in which 12 subjects
received a 2 mg pitavastatin calcium tablet once daily for 6 days.
Inclusion and exclusion criteria
Healthy male and female Chinese volunteers aged 18 to 27
years and with a body mass index between 19 and 24 were eligible
for recruitment. Additional inclusion criteria included a healthy
status conﬁrmed by medical history, physical examination, 12-lead
ECG, laboratory tests (eg, hematology, blood biochemistry, hepatic
function, urinalysis, hepatitis B surface antigen, and tests for
alcohol and other drugs of abuse), and nonsmoking status.
Subjects were excluded from the study if they had any allergies
or history of cardiac, pulmonary, renal, hepatic, gastrointestinal, or
hematologic abnormality or any other acute or chronic disease.
Other exclusion criteria included exposure to any investigational
medication within 30 days of the ﬁrst dose of study medication,
pregnant or nursing women, and women of childbearing potential
not using a highly effective method of birth control.
Ethics
The study was approved by the Independent Ethics Committee
of West China Hospital, Sichuan University (Chengdu, China) and
was conducted in accordance with the Declaration of Helsinki
concerning medical research in human beings and the principles
of the International Conference on Harmonisation Guideline for
Good Clinical Practice. Written informed consent was obtained
from each subject before screening procedures.
Drug administration and sample collection
The study drug administration and sample collection were
performed in the Phase I Study Unit of West China Hospital,
Sichuan University under direct medical supervision. The
researched pitavastatin calcium tablets (batch No. 06100901;
expiration date October 2008) were provided by Yangzi River
Pharmaceuticals Co Ltd (Shanghai, China).
The subjects were admitted to the Phase I Study Unit 1 day
before drug administration and were offered a standard dinner.After an overnight fast (12 hours), subjects received a single dose
of 1 mg, 2 mg, or 4 mg pitavastatin calcium tablet on dosing day in
each single-dose study stage. The pitavastatin calcium tablets were
administered with 200 mL water. Additional water intake was
permitted 2 hours following dosing. Subjects were offered a
standard meal (900 kcal; 30% protein, 60% carbohydrate, and
10% fat) 4 and 10 hours following dosing. Blood samples (4 mL)
were collected from an indwelling catheter inserted in a forearm
vein before and at 0.25 hours, 0.5 hours, 0.75 hours, 1 hours, 1.33
hours, 1.67 hours, 2 hours, 4 hours, 6 hours, 8 hours, 11 hours, 24
hours, and 36 hours following dosing. In the multiple-dose study
stage, subjects received a 2-mg pitavastatin calcium tablet once
daily for 6 days. At the third, fourth, and ﬁfth day, blood samples
(4 mL) were collected before dosing. At the last day of multiple
dosing, blood samples (4 mL) were collected before and at 0.25
hours, 0.5 hours, 0.75 hours, 1 hour, 1.33 hours, 1.67 hours, 2 hours,
4 hours, 6 hours, 8 hours, 11 hours, 24 hours, 34 hours, and 48
hours following dosing. The blood sample was drawn into a plastic
tube with heparin sodium as anticoagulant and then immediately
centrifuged at 3500 revolutions/min for 10 minutes at 41C. The
supernatant plasma was transferred into a polypropylene tube and
stored at –201C until drug analysis.
The volunteers were instructed to abstain from taking any drug,
including over-the-counter medications, for 2 weeks before and
during the study period, and to abstain from alcohol, smoking, intense
physical activity, and caffeine-containing beverages during the study.
Assays of pitavastatin
Plasma pitavastatin was quantiﬁed by a liquid chromatography-
tandem mass spectrometry (LC-MS/MS) method developed and
validated before the clinical study. Plasma pitavastatin quantiﬁca-
tion was conducted in the Research Center for Drug Metabolism of
Jilin University. Chromatography was performed using an Agilent
1100 HPLC system (Agilent Technologies, Santa Clara, California)
equipped with an Agilent Extend C18 column (150 mm  4.6 mm;
5 μm) maintained at 301C. The mobile phase consisted of
acetonitrile-10 mM ammonium acetate in water (45:55 v/v)
delivered at a ﬂow rate of 1 mL/min. Mass spectrometric detection
employed an API 4000 mass spectrometer (AB Sciex, Concord,
Ontario, Canada) equipped with an electrospray ionization source
operated in the negative ion mode. The curtain gases, Gas 1 and
Gas 2, were nitrogen set at 15, 35, and 35 psi, respectively. The ion
spray voltage was adjusted to 5000 V and the source temperature
was set at 5001C. Detection was by multiple reaction monitoring at
unit resolution for Q1 and unit resolution for Q3 with a dwell time of
200 ms/channel. Transitions of [MþH]þ ions for multiple reaction
monitoring were atm/z 421.9-290.1 for pitavastatin andm/z 515.2-
276.1 for internal standard. Declustering potential and collision energy
were 100 V and 38 eV for prostaglandin E1 and 90 V and 60 eV for
internal standard. Mass spectrometric parameters were tuned to
maximize the response of the precursor/product ion combinations.
Data acquisition and integration were controlled by Applied Biosys-
tems Analyst version 1.3 software (New York, USA).
A stock solution of pitavastatin calcium (0.2 mg/mL) was
prepared in water. Calibration standards of pitavastatin were
prepared by diluting the stock solutions with blank plasma to
concentrations of 0.287 ng/mL, 0.957 ng/mL, 2.87 ng/mL, 9.57 ng/
mL, 28.7 ng/mL, 95.7 ng/mL, and 287 ng/mL. Quality control
solutions were prepared independently at concentrations of 0.957
pg/mL, 9.57 pg/mL, and 95.7 pg/mL in the same way. A stock
solution (0.2 mg/mL) of the internal standard, telmisartan in
methanol-water (50:50 v/v), was diluted in methanol-water
(50:50 v/v) to give a 50 ng/mL working internal standard solution.
All solutions were stored at 41C. To 200 μL plasma or calibration
standard or quality control sample in a glass tube, 50 μL formic acid
Z. Luo et al. / Current Therapeutic Research 77 (2015) 52–5754and 50 μL internal standard working solution were added. The
mixture was then shaken with 3 mL diethyl ether-dichloromethane
(3:2 v/v), centrifuged for 5 minutes at 3500 g, and the organic layer
was transferred to another glass tube and evaporated to dryness at
401C under nitrogen. The residue was reconstituted in 150 μL
mobile phase and the 10 μL was injected into the LC-MS/MS system.
Figure 1 shows the chromatograms of a blank plasma sample, a
calibration standard, and plasma sample after pitavastatin admin-
istration. As Figure 1 shows, no signiﬁcant interference was
observed from endogenous substances in plasma at the retention
times of pitavastatin and is the internal standard.
The calibration curve was linear over the range of 0.287 to 287
ng/mL with a typical equation of y ¼ 0.0157x þ 0.000505 (r ¼
0.9980). The inter- and intraday relative standard deviation
of quality-control samples at concentrations of 0.957 ng/mL, 9.57
ng/mL, and 95.7 ng/mL were all o15%; the relative error of the above
3 concentration-level quality control samples were between 1.25%
and 1.92%, supporting the high precision and accuracy of the assay
method. Extraction recoveries of pitavastatin for low-, medium-, and
high-quality control samples were 89.0% (2.1%), 80.7% (0.92%), and
84.2% (3.7%), respectively. Stability tests showed the analyte was
stable in human plasma under the following conditions: at 201C for
80 days, after 3 freeze-thaw cycles (801C to room temperature), and
processed samples at room temperature for 8 hours.PK parameters and statistical analysis
PK parameters were calculated using the noncompartmental
analysis method with WinNonlin version 6.1 (Pharsight Corporation,
Mountain View, California). Cmax and Tmax were obtained directly
from the concentration time data of pitavastatin. AUC0t was calcu-
lated according to the linear trapezoidal rule. AUC01 was calculatedI
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Figure 1. Representative chromatograms of (A) blank plasma sample, (B) plasma sampl
hours following dosing. I ¼ pitavastatin. II ¼ telmisartan.as the sum of AUC0t and Ct/λ. Ct was the last measured concen-
tration and λwas the slope of linear regression of the log-transformed
concentration-time curve. Value of t1/2 was calculated as the ratio of
0.693/λ. All statistical analyses were performed using SAS version 9.2
(SAS Institute Inc, Cary, North Carolina). Independent-samples t tests
or nonparametric tests were used to determine statistically signiﬁcant
differences between the PK parameters. A linear-regression model
was used to determine the dose proportionality. For all the analyses, P
o 0.05 was considered statistically signiﬁcant.
Tolerability assessment
The subjects were under continuous medical supervision in the
Phase I Unit during the study. Data on adverse events were collected
by trained study nurses or investigators using nonleading and open-
ended verbal questioning. Vital signs were measured at screening,
predose, and 0.5 hours, 1 hour, 2 hours, 4 hours, and 24 hours
postdose on each dosing day. Physical examination was performed
at screening, predose, and 24 hours postdose on each dosing day. All
information was recorded in the case-report form. Twelve-lead ECG
and laboratory tests, including hematology, blood biochemistry,
hepatic function, and urinalysis were conducted at screening and
at the end of the study. All laboratory tests were performed at the
laboratory of West China Hospital, Sichuan University, which was
authenticated by the College of American Pathologists.Results
Study population
We enrolled 12 subjects (6 male and 6 female) into the study,
with the mean age (SD) of 24.6 (1.0) years (range ¼ 23–26 years),I
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Figure 2. Mean plasma concentration-time curves of pitavastatin after single-dose
administration of 1 mg, 2 mg, and 4 mg pitavastatin calcium tablets.
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cm (range ¼ 155.0–169.0 cm). All subjects completed the 4 study
stages except 1 male subject who withdrew from the study
following the 1 mg and 2 mg single-dose stage because of with-
drawing the informed consent. So, 12 subjects’ PK data were
obtained for the 1 mg and 2 mg single-dose study and 11 subjects’
PK data were obtained for the 4 mg single-dose and multiple-
dose study.PK properties
The mean plasma pitavastatin concentration-time curves are
shown in Figures 2 and 3. The primary PK parameters are
presented in Table I. All measurements are stated as the resulting
mean (SD) values. Following a single dose of 1 mg, 2 mg, and 4 mg
pitavastatin, the drug was rapidly absorbed and the Tmax values
were 0.63 (0.17) hours, 0.65 (0.17) hours, and 0.79 (0.36) hours,
respectively. For the 1 mg, 2 mg, and 4 mg dose levels, Cmax values
were 66.80 (16.32) ng/mL, 106.09 (31.59) ng/mL, and 232.91
(66.42) ng/mL, respectively; AUC036 values were 190.04 (38.97)
ng/mL/h, 307.87 (57.94) ng/mL/h, and 785.10 (166.08) ng/mL/h,
respectively; and t1/2 values were 10.99 (2.70) hours, 9.52 (2.58)
hours, and 10.38 (4.28) hours, respectively. The dose proportion-
ality of Cmax and AUC after single dosing was analyzed by linear
regression. The linear regression equation for Cmax, AUC0t, and
AUC01 were y ¼ 56.41x þ 3.56, y ¼ 203.55x  47.80, and y ¼
213.23x  46.61, respectively. The correlation coefﬁcient for Cmax,
AUC0t, and AUC01 were 0.86, 0.92, and 0.91, respectively.
P value was 0.000 for Cmax, AUC0t, and AUC01 linear regression
analysis, suggesting that single dosing of 1 mg, 2 mg, and 4 mg
pitavastatin resulted in linear plasma PK parameters.
After repeated administration of pitavastatin, mean plasma
concentrations attained predose on Day 4 and Day 5 of multiple
dosing and at 24 hours postdose on Day 6 were similar, suggesting
that a steady state of plasma pitavastatin concentration was
achieved around Day 4 of multiple dosing. The steady-state con-
centration and steady-state trough concentration were 11.05 (4.85)
ng/mL and 2.58 (0.92) ng/mL, respectively. Multiple-dose admin-
istration of pitavastatin was characterized by some similar PK
parameters with single-dose administration. A rapid absorption0
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Figure 3. Mean plasma concentration-time curves of pitavastatin after single-dose
and multiple-dose administration of 2 mg pitavastatin calcium tablets.(Tmax ¼ 0.68 [0.20] hours) and marked peak concentration 90.99
(36.88) ng/mL were observed. AUC048 and AUCss were 306.28
(130.02) ng/mL/h and 256.16 (116.34) ng/mL/h, respectively. Com-
pared with single dosing, the elimination half-life after multiple
dosing was signiﬁcantly prolonged, which amounted to 13.31 (2.58)
hours (P ¼ 0.002). The mean apparent volume of distribution was
170.02 L and mean plasma clearance was 8.54 L/h after multiple
dosing, both of which were also signiﬁcantly different from those
after single dosing (P o 0.05). However, the Cmax or AUC0t did not
increase after repeated administration and the accumulation index,
which was calculated as AUCsingle-dose/AUCmultiple-dose, was 0.98
(0.28), indicating no accumulation of pitavastatin.
Table II shows the comparison of the main PK parameters
between the male and female subjects and reveals no signiﬁcant
differences between groups, suggesting that sex does not appear
to affect the PK properties of pitavastatin.
Tolerability
Single doses of 1 mg, 2 mg, or 4 mg pitavastatin calcium tablets
and multiple doses of 2 mg pitavastatin calcium tablets once daily
for 6 days were well tolerated by all the subjects. One male subject
reported a stuffy and running nose that was diagnosed as common
cold by investigators. The above symptoms were rated as mild and
considered unrelated to the study treatment. No other adverse
events were observed or reported. Physical examination, electro-
cardiograms, and laboratory tests did not suggest any clinically
signiﬁcant abnormality.Discussion
We investigated the PK properties of pitavastatin in healthy
Chinese volunteers. We created and validated a LC-MS/MS method
to quantify the plasma pitavastatin. The method validation results
of speciﬁcity, precision, accuracy, recovery, and stability suggest
that our method was suitable for the assay of pitavastatin in
human plasma.
In our study, after single dosing of 1 mg, 2 mg, and 4 mg
pitavastatin in healthy Chinese volunteers, the peak plasma con-
centration and AUC of pitavastatin were proportional to the dose,
suggesting linear plasma PK properties. Our study revealed that
pitavastatin is rapidly absorbed after oral administration, reaching
peak concentration within 1 hour. The elimination half-life of
pitavastatin after single dosing in healthy Chinese volunteers is
about 10 hours. The PK ﬁndings from our study are in agreement
with those from studies in the published literature.10–12 In our
study, pitavastatin reached steady state around the fourth day on
repeated daily administration, which is in accordance with the
published literature.10
Interestingly, we found that pitavastatin showed somewhat
different distribution and elimination characteristics after
repeated administration compared with single dosing. The elim-
ination half-life after multiple dosing was signiﬁcantly prolonged
compared with that following single dosing (from 9.52 [2.58] to
13.31 [2.58] hours). Furthermore, the mean apparent volume of
distribution after multiple dosing increased to 170.02 L compared
with that after single dosing (86.93 L); the mean plasma clearance
increased from 6.48 L/h (single dosing) to 8.54 L/h following
multiple dosing. Those differences were statistically signiﬁcant
(P o 0.05) and furthermore, in our opinion, clinically signiﬁcant.
Pitavastatin is reported to be highly protein bound, primarily to
albumin and alpha-1-acid glycoprotein, with a binding ratio of
96%.13,14 Animal studies15,16 indicated that pitavastatin was widely
distributed in tissue, achieving the highest levels in the liver,
where levels of pitavastatin were approximately 54 times higher
Table I
Primary pharmacokinetic (PK) parameters of pitavastatin after single-dose administration of 1 mg, 2 mg, and 4 mg pitavastatin calcium tablets and multiple-dose
administration of 2 mg pitavastatin calcium tablets in healthy Chinese volunteers.*
PK parameter
Single dose Multiple dose
1 mg (n ¼ 12) 2 mg (n ¼ 12) 4 mg (n ¼ 11) 2 mg (n ¼ 11)
Cmax, ng/mL 66.80 (16.32) 106.09 (31.59) 232.91 (66.42) 90.99 (36.88)
Tmax, h 0.63 (0.17) 0.65 (0.17) 0.79 (0.36) 0.68 (0.20)
t1/2, h 10.99 (2.70) 9.52 (2.58) 10.38 (4.28) 13.31 (2.58)
AUC0t, ng/mL/h 190.04 (38.97) 307.87 (57.94) 785.10 (166.08) 306.28 (130.02)
AUC01, ng/mL/h 205.67 (45.62) 321.25 (64.02) 827.59 (190.55) 321.68 (130.56)
Volume of distribution, L 79.86 (26.16) 86.93 (21.82) 72.45 (19.56) 170.02 (89.75)
Mean plasma clearance, L/h 5.09 (1.13) 6.48 (1.41) 5.13 (1.45) 8.54 (2.90)
Cav, ng/mL ─ ─ ─ 11.05 (4.85)
Cmin, ng/mL ─ ─ ─ 2.58 (0.92)
AUCss, ng/mL/h ─ ─ ─ 265.16 (116.34)
n All values are mean (SD).
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hepatoselectivity of pitavastatin following oral administration
makes it minimally exposed to peripheral tissue. Our ﬁndings
about the change of apparent volume of distribution suggest that
pitavastatin is more widely distributed after repeated dosing
compared with a single administration. The mechanism of such
change might be as follows: after single dosing, the plasma
pitavastatin is still in the dynamic distribution processing from
peripheral tissue (blood) to liver, and multiple dosing made the
distribution saturated. Therefore, pitavastatin is more widely
distributed following repeated dosing compared with single dos-
ing. Furthermore, although the plasma clearance of pitavastatin
following multiple dosing increased, it could not offset the effect of
distribution increase, resulting in a prolonged elimination half-life
compared with single dosing. However, the peak plasma concen-
tration and AUC did not increase after repeated administration.
The accumulation index, calculated as AUCmultiple-dose/AUCsingle-dose
and Cmax, multiple-dose/Cmax, single-dose, was 0.98 (0.28) and
0.85 (0.23), respectively. These facts indicated no accumulation
of pitavastatin following repeated administration and even
smaller exposure of the drug in plasma, minimizing drug toxi-
city and ensuring the safety of multiple dosing in clinical
treatment.
In our study, the comparison of the PK parameters between the
male and female subjects revealed no signiﬁcant differences
between groups, suggesting that sex did not appear to affect the
PK properties of pitavastatin. Dose adjustments based on sex in the
Chinese population are not anticipated.Table II
Comparison of pharmacokinetic (PK) parameters in male and female subjects after single
dose of 2 mg pitavastatin calcium tablets.*
PK parameter
1 mg single dose 2 mg single dose
Male
(n ¼ 6)
Female
(n ¼ 6)
P Male
(n ¼ 6)
Female
(n ¼ 6)
Cmax, ng/mL 62.63 (9.71) 70.98
(21.21)
0.401 98.40
(18.73)
113.78
(41.27)
Tmax, h 0.58 (0.13) 0.67 (0.20) 0.465 0.63 (0.14) 0.67 (0.20)
t1/2, h 12.28 (2.73) 9.69 (2.13) 0.098 9.08 (3.34) 9.95 (1.76)
AUC0t,ng/mL/h 175.64 (39.53) 204.44
(35.79)
0.215 285.77
(41.22)
329.96
(67.19)
Volume of
distribution, L
86.44 (21.96) 73.28
(9.03)
0.419 86.41
(18.82)
87.45
(26.32)
Mean plasma
clearance, L/h
5.52 (1.28) 4.65 (0.84) 0.194 6.85 (1.08) 6.11 (1.69)
Cav, ng/mL ─ ─ ─ ─ ─
AUCss,ng/mL/h ─ ─ ─ ─ ─
n All values are mean (SD).Pitavastatin is a new HMG-CoA reductase inhibitor with a novel
cyclopropyl moiety, which results in several differences compared
with other statins. For example, pitavastatin does not undergo
signiﬁcant hepatic metabolism through the cytochrome P450
system. Instead, pitavastatin’s cyclopropyl group diverts the drug
away from metabolism by cytochrome P3A4 and allows only a
small amount of clinically insigniﬁcant metabolism by cytochrome
P2C9, minimizing its potential to cause many drug–drug inter-
actions.17 Pitavastatin is rapidly taken up into the liver through
organic anion transporting polypeptide 1B1 (OATP1B1)18,19 and
the polymorphism of OATP1B1 plays an important role in the
disposition of pitavastatin in the human body. Chung et al20
reported AUC and Cmax of pitavastatin to be 1.4- and 8-fold higher,
respectively, in subjects heterozygous for the OATP*15 allele
compared with those without this allele. A study by Wen et al21
showed that the disposition of pitavastatin is signiﬁcantly altered
by the 388A4G genetic variation; that is, the AUC and Cmax values
in the OATP 388GA þ 388GG mutant group were about 80% and
71% higher than corresponding values for the 388AA wild-type
group and the oral elimination of pitavastatin in the OATP 388GA
þ 388GG mutant group was about 35% lower than in the 388AA
wild-type group. A study22 showed that the OATP1B1*15 allele
frequencies differed statistically between Asian populations.
Meanwhile, Xu et al23 reported the frequencies of 388A4G and
521T4C variant alleles in the Chinese population are similar to
those in the Japanese population, but signiﬁcantly different from
those in whites and blacks. The OATP1B1 polymorphism may
explain the interindividual variations of pitavastatin PK properties-dose administration of 1 mg, 2 mg, 4 mg pitavastatin calcium tablets and multiple-
4 mg single dose 2 mg multiple dose
P Male
(n ¼ 5)
Female
(n ¼ 6)
P Male
(n ¼ 5)
Female
(n ¼ 6)
P
0.425 209.00
(38.03)
252.83
(81.35)
0.299 86.18 (8.56) 98.82 (51.18) 0.714
0.789 0.65 (0.22) 0.90 (0.44) 0.286 0.60 (0.14) 0.75 (0.22) 0.237
0.585 8.72 (1.32) 11.78 (5.48) 0.273 13.77 (1.50) 12.93 (3.33) 0.619
0.200 689.53
(157.68)
764.74
(136.13)
0.145 288.83 (51.74) 320.83 (176.38) 0.706
0.938 72.19
(10.03)
72.67
(26.16)
0.465 164.54 (35.65) 174.59 (122.63) 0.715
0.200 5.91 (1.57) 4.98 (1.04) 0.120 8.25 (1.27) 8.78 (3.93) 0.782
─ ─ ─ ─ 10.32 (1.86) 11.65 (6.58) 0.674
─ ─ ─ ─ 247.74 (44.61) 279.67 (157.86) 0.674
Z. Luo et al. / Current Therapeutic Research 77 (2015) 52–57 57in our study to some extent. However, we lacked the volunteers’
genetic polymorphism data, which is 1 of the limitations of
the study.
Lactonization is the major metabolic pathway of pitavastatin in
the human body.24 In our study, we measured plasma pitavastatin,
but did not include its main metabolite (pitavastatin lactone
[Pi-LAC]) for measurement, which is another limitation of our
study. In a recent study in Chinese healthy volunteers, simulta-
neous determination of pitavastatin and Pi-LAC was conducted.12
The authors reported the interconversion of pitavastatin and Pi-
LAC in human plasma. Interestingly, the authors found pitavastatin
is stable and did not convert to Pi-LAC. That is the reason why the
interconversion phenomenon has been ignored in most reports of
quantiﬁcation of pitavastatin.25,26Conclusions
In healthy Chinese volunteers, both single and multiple dosing
of pitavastatin are characterized by rapid absorption and sustained
concentration of pitavastatin. Linear PK data can be used to
describe the PKs from single-dosing data. We found that pitavas-
tatin steady-state concentrations were reached around the fourth
day of repeated daily administration. Although multiple dosing of
pitavastatin showed different distribution and elimination charac-
teristics compared with single dosing, pitavastatin exhibited no
accumulation after repeated administration. Sex did not appear to
affect the PK properties of pitavastatin. All the pitavastatin doses
tested were well tolerated.Acknowledgments
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